KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Operating Expenses (2016 - 2025)

Resmed's Operating Expenses history spans 17 years, with the latest figure at $387.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 15.88% year-over-year to $387.1 million; the TTM value through Dec 2025 reached $1.5 billion, up 11.44%, while the annual FY2025 figure was $1.4 billion, 2.56% up from the prior year.
  • Operating Expenses reached $387.1 million in Q4 2025 per RMD's latest filing, up from $374.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $387.1 million in Q4 2025 to a low of $223.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $309.4 million, with a median of $317.6 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: grew 28.08% in 2023, then dropped 10.17% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $255.6 million in 2021, then grew by 17.18% to $299.5 million in 2022, then increased by 24.14% to $371.8 million in 2023, then dropped by 10.17% to $334.0 million in 2024, then rose by 15.88% to $387.1 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Operating Expenses are $387.1 million (Q4 2025), $374.3 million (Q3 2025), and $365.5 million (Q2 2025).